Navigation Links
EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
Date:11/4/2007

bout the prospects for Ceplene's approval, and the application continues to be reviewed according to the expected timetable. We now await the next regulatory milestone, the CHMP's Day 180 Assessment Report and List of Outstanding Issues, which we expect to receive in late November. We will continue to work closely with the EMEA and the CHMP to address any outstanding issues so that the CHMP will be in a position to render a positive opinion."

EpiCept reported progress with several of its key product candidates during the third quarter and subsequent weeks, including:

Ceplene(TM) - a registration-stage compound for the treatment of Acute Myeloid Leukemia (AML), the most common type of leukemia in adults, currently undergoing regulatory review by the European Medicines Agency for the Evaluation of Medicinal Products (EMEA). During the third quarter EpiCept reported that the Marketing Authorization Application (MAA) for Ceplene is advancing according to the anticipated regulatory timetable. The company submitted its full responses to the Day 120 Consolidated List of Questions to the Committee for Human Medicinal Products (CHMP) and EpiCept's staff and consultants met with EMEA officials and CHMP representatives to discuss these responses on September 17, 2007. EpiCept expects to receive the CHMP's Day 180 Assessment Report and List of Outstanding Issues in late November 2007. The company continues to be optimistic about the prospects for approval for this product in the first half 2008. If the application for Ceplene continues to follow usual E.U. regulatory timelines, the likely regulatory milestone for Ceplene following receipt of the Day 180 List of Outstanding Issues will be the option, if required, for EpiCept to attend a Day 181 Oral Explanation with the CHMP to resolve any outstanding issues.

EpiCept NP-1 - a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affect more tha
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
3. Autopsy reports could be valuable and informative
4. China reports declining number of SARS Cases
5. Russia Reports First SARS Case
6. Research reports that c-section deliveries are rising
7. Jharkhand reports 13,000 Malaria cases
8. Uganda Reports Failure To Contain Sleeping Sickness
9. WHO reports 36 million deaths world wide due to chronic diseases
10. Reports of Hantavirus infection in India raise concerns
11. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... German . ... the ,International Space Station Research Competition, with their project ... scientists will see the International Space Station crew perform ... two proteins of the hepatitis C virus under microgravity ... Space Station is scheduled to lift off from Cape ...
(Date:9/18/2014)... 2014 According to a new market report ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 77607.7 million in 2013 and is ... to 2020, to reach an estimated value of USD 115474.9 ... market is growing at a rapid pace due to increasing ...
(Date:9/18/2014)... September 18, 2014 “Awesome” is the ... (Smart Teens Accepting Responsibility Today) Internship Program at ARDX ... Darcy C. describe the program as “Inspirational” and “Life-changing,” ... idea about what they would be doing during their ... do food runs and other mindless tasks,” but, instead ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, ... may be associated with increased odds of developing Parkinson,s ... research suggests. The study, which did not prove ... suggested that the migraine-Parkinson,s association was stronger in women ... warning sign of a pending attack that includes flashes ...
(Date:9/18/2014)... 2014 How much is a serving? ... the factors contributing to the obesity epidemic in the ... serving and how to manage portion size during the ... 3 at Humility House, 755 Ohltown Road, Austintown. , ... the informational discussion and answer questions from 12:30 to ...
Breaking Medicine News(10 mins):Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:HMHP Workshop Addresses Portion Control 2
... and poultry products from Taiwan, Hong Kong, and four ... to 17.//,The step has come as a precaution against ... ,Last month, Pakistan put a similar ban on ... Indonesia, Cambodia, Laos, Russia, Kazakhstan, Mongolia, Turkey, Greece and ...
... is a major factor increasing the cholesterol level in ... by the body in moderate amounts, can lead to ... Lena Brydon of University College London examined 199 healthy ... to stress and whether their reaction can increase cholesterol ...
... bird flu, even as the government has given approval to ... ,The latest outbreaks of the deadly H5N1 strain of the ... province of Yunnan and the northwestern region of Ningxia, the ... died in Yunnan's Chuxiong district Thursday, and 230 died in ...
... of its super-speciality hospital chain with a 280-bed hospital ... ,"We have embarked on the construction of a ... be ready by 2007-end. We also plan Greenfield projects ... president, told IANS., ,Unlike the existing 110-bed cardiac ...
... of more than 1,200 children, whose organs were removed after ... an average of about ?2,900 in a compensation deal announced ... is the apex body had fought the cases involving ... ago to a total figure of around ?3.6 million for ...
... could be putting their health at risk by failing ... other health professionals.// ,The survey of more than ... Professions Council (HPC), found that about 81% of people ... were oblivious to whether they were properly qualified to ...
Cached Medicine News:Health News:Wockhardt Group Plans Hospital In Delhi By End-2007 2Health News:Organ Scandals Compensation And The Aftermath 2Health News:Credentials Of Specialists Need To Be Checked 2
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... OF ELAGOLIX ON BONE MINERAL DENSITY, SAN DIEGO, ... announced today that the elagolix 0603 Phase IIb trial,(Petal ... subject,completed her Week 24 study visit in early June. ... on bone mineral density (BMD) as,the primary endpoint using ...
... Prevention and Control Professionals Cite,Greatest Needs for ... More Environmental Services and Time-Saving High Tech ... than three out of four,(76%) infection prevention ... implemented additional measures to prevent the,transmission of ...
Cached Medicine Technology:Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 2Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 3Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: